The FDA opened a request for feedback ahead of a public meeting to evaluate an expedited review voucher pilot that has already accelerated four drug approvals. The agency is soliciting stakeholder input on the pilot’s implementation, outcomes and potential refinements before the summer meeting, signaling regulatory caution as the program draws scrutiny over transparency and priority setting. The review comes as industry observers debate the program’s trade‑offs: faster access to priority medicines versus fairness, political optics and resource allocation across applications. Input from manufacturers, patient groups and payers could shape whether the voucher program expands, is restructured, or becomes more narrowly targeted to specific public‑health priorities.